SCHEMBL302570

SCHEMBL302570

NS(=O)(=O)c1ccccc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PTGES2 Q9H7Z7 2/20 0.51
CA2 P00918 8/20 0.50
CA1 P00915 7/20 0.50
SLC22A12 Q96S37 6/20 0.50
CA9 Q16790 5/20 0.50
CA6 P23280 4/20 0.50
CA5A P35218 4/20 0.50
CA4 P22748 3/20 0.50
CA12 O43570 3/20 0.50
CA7 P43166 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
CA14 Q9ULX7 2/20 0.50
CYP2C9 P11712 2/20 0.50
HSD11B1 P28845 1/20 0.46
ALDH1A1 P00352 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
SLC22A11 Q9NSA0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418255 1.00 MEN1 (0.56) MEN1KMT2APTGES2CA2CA1
Hydrochloric Acid SCHEMBL2640190 0.98 MEN1 (0.55) MEN1KMT2APTGES2CA2CA1
Bromide SCHEMBL16335049 0.98 MEN1 (0.55) MEN1KMT2APTGES2CA2CA1
Formic Acid SCHEMBL19617348 0.91 PTGES2 (0.49) MEN1KMT2APTGES2CA2CA1
Trifluoroacetic Acid SCHEMBL15918323 0.89 KMT2A (0.49) MEN1KMT2APTGES2CA2CA1
SCHEMBL18341141 0.88 MEN1 (0.50) MEN1KMT2APTGES2CA2CA1
SCHEMBL2452803 0.84 SCN9A (0.48) MEN1KMT2APTGES2CA2CA1
SCHEMBL29874131 0.82 MEN1 (0.60) MEN1KMT2ASLC22A12CYP2C9HSD11B1
SCHEMBL3625928 0.82 MEN1 (0.60) MEN1KMT2ASLC22A12CYP2C9HSD11B1
SCHEMBL2512044 0.82 CA2 (0.46) MEN1KMT2APTGES2CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 US claimed
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 US claimed
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 US claimed
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
CN-115117442-B Single ion gel polymer electrolyte, preparation and application thereof 华中科技大学 2024-10-22 CN claimed
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES MONDEGO BIO, LDA. (PT) 2024-08-08 US claimed
EP-4408432-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN claimed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN claimed
EP-4288412-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME Rappta Therapeutics Oy (FI) 2023-12-13 EP claimed
WO-2005030209-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-04-07 WO claimed
CN-1589101-A Herbicides containing substituted thien-3-ylsulfonylamino (thio) carbonyltriazolin (thi) one compounds BAYER CROPSCIENCE GMBH (DE) 2005-03-02 CN claimed
WO-2004043917-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2004-05-27 WO claimed
WO-2004010779-A2 SYNERGISTICALLY ACTING HERBICIDAL MIXTURES BASF AKTIENGESELLSCHAFT (DE) 2004-02-05 WO claimed
EP-1301480-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2003-04-16 EP claimed
WO-2002006223-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-01-24 WO claimed
CN-1269136-A Fluoric alkenyl compound and use as insect repellent agent MONSANTO CO (US) 2000-10-11 CN claimed
EP-0850218-A1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-07-01 EP claimed
EP-0132230-B1 PROCESS FOR THE PREPARATION OF SULFONYL UREA CIBA-GEIGY AG (CH) 1988-10-05 EP claimed
EP-0132230-A2 Process for the preparation of sulfonyl urea CIBA-GEIGY AG (CH) 1985-01-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 MEN1 2901/4885KMT2A 3057/4885PTGES2 2076/4885
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES PPM1A, TH, PPM1G MEN1 2523/4885KMT2A 1362/4885PTGES2 1010/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 MEN1 3316/4885KMT2A 4062/4885PTGES2 3209/4885
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors CDK2, CCNK, CCNI MEN1 2859/4885KMT2A 905/4885PTGES2 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.